The principle objective of formulation of lipid-based drugs is to enhance their bioavailability. The use of lipids in drug delivery is no more a new trend now but is still the promising concept. Lipid-based drug delivery systems (LBDDS) are one of the emerging technologies designed to address challenges like the solubility and bioavailability of poorly water-soluble drugs. Lipid-based formulations can be tailored to meet a wide range of product requirements dictated by disease indication, route of administration, cost consideration, product stability, toxicity, and efficacy. These formulations are also a commercially viable strategy to formulate pharmaceuticals, for topical, oral, pulmonary, or parenteral delivery. In addition, lipid-based formulations have been shown to reduce the toxicity of various drugs by changing the biodistribution of the drug away from sensitive organs. However, the number of applications for lipid-based formulations has expanded as the nature and type of active drugs under investigation have become more varied. This paper mainly focuses on novel lipid-based formulations, namely, emulsions, vesicular systems, and lipid particulate systems and their subcategories as well as on their prominent applications in pharmaceutical drug delivery. 1. Introduction In these modern days, many significant efforts have been applied to use the potentials of lipid-based drug delivery systems, as it provides the suitable means of site specific as well as time controlled delivery of drugs with different molecular weight, either small or large, and also the bioactive agents [1, 2]. Poorly water-soluble drugs are challenging for the formulation scientists with regard to solubility and bioavailability. Lipid-based drug delivery systems (LBDDS) have shown the effective size dependent properties so they have attracted a lot of attention. Also LBBDS have taken the lead because of obvious advantages of higher degree of biocompatibility and versatility. These systems are commercially viable to formulate pharmaceuticals for topical, oral, pulmonary, or parenteral delivery. Lipid formulations can be modified in various ways to meet a wide range of product requirements as per the disease condition, route of administration, and also cost product stability, toxicity, and efficacy. Lipid-based carriers are safe and efficient hence they have been proved to be attractive candidates for the formulation of pharmaceuticals, as well as vaccines, diagnostics, and nutraceuticals [3]. Hence, lipid-based drug delivery (LBDD) systems have gained much importance in the
References
[1]
I. Brigger, C. Dubernet, and P. Couvreur, “Nanoparticles in cancer therapy and diagnosis,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 631–651, 2002.
[2]
J. Panyam and V. Labhasetwar, “Biodegradable nanoparticles for drug and gene delivery to cells and tissue,” Advanced Drug Delivery Reviews, vol. 55, no. 3, pp. 329–347, 2003.
[3]
R. H. Müller, M. Radtke, and S. A. Wissing, “Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations,” Advanced Drug Delivery Reviews, vol. 54, no. 1, pp. S131–S155, 2002.
[4]
P. Gershkovich, K. M. Wasan, and C. A. Barta, “A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 25, no. 6, pp. 545–584, 2008.
[5]
？. Paveli？, N. ？kalko-Basnet, J. Filipovi？-Gr？i？, A. Martinac, and I. Jal？enjak, “Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir,” Journal of Controlled Release, vol. 106, no. 1-2, pp. 34–43, 2005.
[6]
H. Benameur, “Liquid and semi-solid formulations for enhancing oral absorption,” Bulletin Technique Gattefossé, vol. 99, no. 1, pp. 63–75, 2006.
[7]
C. W. Pouton and C. J. H. Porter, “Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 625–637, 2008.
[8]
C. J. H. Porter, N. L. Trevaskis, and W. N. Charman, “Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs,” Nature Reviews Drug Discovery, vol. 6, no. 3, pp. 231–248, 2007.
[9]
A. Dahan and A. Hoffman, “Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs,” Journal of Controlled Release, vol. 129, no. 1, pp. 1–10, 2008.
[10]
C. W. Pouton, “Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system,” European Journal of Pharmaceutical Sciences, vol. 29, no. 3-4, pp. 278–287, 2006.
[11]
P. P. Constantinides, “Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects,” Pharmaceutical Research, vol. 12, no. 11, pp. 1561–1572, 1995.
[12]
R. G. Strickley, “Solubilizing excipients in oral and injectable formulations,” Pharmaceutical Research, vol. 21, no. 2, pp. 201–230, 2004.
[13]
J. B. Cannon and M. A. Long, “Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery, part II,” in Oral Applications, vol. 16, pp. 227–254, 2008.
[14]
C. W. Pouton, “Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems,” European Journal of Pharmaceutical Sciences, vol. 11, no. 2, pp. S93–S98, 2000.
[15]
E. B. Souto and R. H. Muller, Nanoparticulate Drug Delivery Systems, vol. 166, Informa Healthcare, New York, NY, USA, 2007.
[16]
C. J. H. Porter, C. W. Pouton, J. F. Cuine, and W. N. Charman, “Enhancing intestinal drug solubilisation using lipid-based delivery systems,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 673–691, 2008.
[17]
B. Chauhan, S. Shimpi, and A. Paradkar, “Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique,” European Journal of Pharmaceutical Sciences, vol. 26, no. 2, pp. 219–230, 2005.
[18]
B. Chauhan, S. Shimpi, and A. Paradkar, “Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique,” AAPS PharmSciTech, vol. 6, no. 3, pp. E405–E409, 2005.
[19]
N. Venkatesan, J. Yoshimitsu, Y. Ohashi et al., “Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs,” International Journal of Pharmaceutics, vol. 310, no. 1-2, pp. 46–52, 2006.
[20]
N. Venkatesan, J. Yoshimitsu, Y. Ito, N. Shibata, and K. Takada, “Liquid filled nanoparticles as a drug delivery tool for protein therapeutics,” Biomaterials, vol. 26, no. 34, pp. 7154–7163, 2005.
[21]
Y. Ito, T. Kusawake, M. Ishida, R. Tawa, N. Shibata, and K. Takada, “Oral solid gentamicin preparation using emulsifier and adsorbent,” Journal of Controlled Release, vol. 105, no. 1-2, pp. 23–31, 2005.
[22]
O. Chambin and V. Jannin, “Interest of multifunctional lipid excipients: case of Gelucire 44/14,” Drug Development and Industrial Pharmacy, vol. 31, no. 6, pp. 527–534, 2005.
[23]
B. Evrard, K. Amighi, D. Beten, L. Delattre, and A. J. Mo？s, “Influence of melting and rheological properties of fatty binders on the melt granulation process in a high-shear mixer,” Drug Development and Industrial Pharmacy, vol. 25, no. 11, pp. 1177–1184, 1999.
[24]
A. Royce, J. Suryawanshi, J. Shah, and K. Vishnupad, “Alternative granulation technique: melt granulation,” Drug Development and Industrial Pharmacy, vol. 22, pp. 917–924, 1996.
[25]
A. Seo and T. Sch？fer, “Melt agglomeration with polyethylene glycol beads at a low impeller speed in a high shear mixer,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 52, no. 3, pp. 315–325, 2001.
[26]
A. Seo, P. Holm, H. G. Kristensen, and T. Sch？fer, “The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer,” International Journal of Pharmaceutics, vol. 259, no. 1-2, pp. 161–171, 2003.
[27]
S. L. Shimpi, B. Chauhan, K. R. Mahadik, and A. Paradkar, “Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13,” Pharmaceutical Research, vol. 22, no. 10, pp. 1727–1734, 2005.
[28]
C. Thies, R. Dos Santos, J. Richard, V. Vandevelde, H. Rolland, and J.-P. Benoit, “A supercritical fluid-based coating technology 1: process considerations,” Journal of Microencapsulation, vol. 20, no. 1, pp. 87–96, 2003.
[29]
I. R. Dos Santos, C. Thies, J. Richards et al., “A supercritical fluid-based coating technology. 2: solubility considerations,” Journal of Microencapsulation, vol. 20, no. 1, pp. 97–109, 2003.
[30]
S. Sethia and E. Squillante, “Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method,” Journal of Pharmaceutical Sciences, vol. 91, no. 9, pp. 1948–1957, 2002.
[31]
S. Sethia and E. Squillante, “In vitro-in vivo evaluation of supercritical processed solid dispersions: permeability and viability assessment in Caco-2 cells,” Journal of Pharmaceutical Sciences, vol. 93, no. 12, pp. 2985–2993, 2004.
[32]
L. J. Naylor, V. Bakatselou, N. Rodriguez-Hornedo, N. D. Weiner, and J. B. Dressman, “Dissolution of steroids in bile salt solutions is modified by the presence of lecithin,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 41, no. 6, pp. 346–353, 1995.
[33]
C. J. H. Porter and W. N. Charman, “In vitro assessment of oral lipid based formulations,” Advanced Drug Delivery Reviews, vol. 50, no. 1, pp. S127–S147, 2001.
[34]
L. Wei, P. Sun, S. Nie, and W. Pan, “Preparation and evaluation of SEDDS and SMEDDS containing carvedilol,” Drug Development and Industrial Pharmacy, vol. 31, no. 8, pp. 785–794, 2005.
[35]
S. Prabhu, M. Ortega, and C. Ma, “Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam,” International Journal of Pharmaceutics, vol. 301, no. 1-2, pp. 209–216, 2005.
[36]
G. A. Edwards, C. J. H. Porter, S. M. Caliph, S. Khoo, and W. N. Charman, “Animal models for the study of intestinal lymphatic drug transport,” Advanced Drug Delivery Reviews, vol. 50, no. 1-2, pp. 45–60, 2001.
[37]
F. Seeballuck, M. B. Ashford, and C. M. O'Driscoll, “The effects of Pluronic block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells,” Pharmaceutical Research, vol. 20, no. 7, pp. 1085–1092, 2003.
[38]
M. Rawat, D. Singh, S. Saraf, and S. Saraf, “Lipid carriers: a versatile delivery vehicle for proteins and peptides,” Yakugaku Zasshi, vol. 128, no. 2, pp. 269–280, 2008.
[39]
A. J. Almeida and E. Souto, “Solid lipid nanoparticles as a drug delivery system for peptides and proteins,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 478–490, 2007.
[40]
W. Choi, J. Kim, S. Choi, J. Park, W. S. Ahn, and C. Kim, “Low toxicity of cationic lipid-based emulsion for gene transfer,” Biomaterials, vol. 25, no. 27, pp. 5893–5903, 2004.
[41]
J. B. Cannon, “Chemical and physical stability considerations for lipid-based drug formulations,” American Pharmaceutical Review, vol. 10, pp. 132–138, 2007.
P. Maincent, “The regulatory environment: the challenges for lipid-based formulations,” Bulletin Technique Gattefossé, vol. 100, pp. 47–49, 2007.
[45]
M. Chen, “Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 768–777, 2008.
